ScreenerHero

FBLG FibroBiologics, Inc.

NAS · US · Healthcare · Biotechnology · fibrobiologics.com
1.110USD-2.63%Mkt Cap: 7.72M $P/E: —

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline in…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.47BUSDP/E 29.3
MRNA
Moderna, Inc.
$78.65BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.14BUSDP/E 18.3
ARGX
argenx SE
$51.48BUSDP/E 31.2
ARGX
argenx SE
$48.23BUSDP/E 31.4
UCB
UCB SA
$41.82BUSDP/E 17.8
RVMD
Revolution Medicines, Inc.
$40.32BUSD
ONC
BeOne Medicines AG
$39.83BUSDP/E 62.6
RPRX
Royalty Pharma plc
$32.48BUSDP/E 29.9
ALNY
Alnylam Pharmaceuticals, Inc.
$30.04BUSDP/E 37.9
ROIV
Roivant Sciences Ltd.
$24.71BUSD
BNTX
BioNTech SE
$23.13BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
GMAB
Genmab A/S
$22.17BUSDP/E 28.4
INSM
Insmed Incorporated
$21.94BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$14.65BUSDP/E 17.1
EXEL
Exelixis, Inc.
$14.62BUSDP/E 18.6
JAZZ
Jazz Pharmaceuticals plc
$14.44BUSDP/E 15.2
SMMT
Summit Therapeutics Inc.
$13.70BUSD

Key Statistics

Company
Market Cap7.72M USD
Enterprise Value5.47M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-18.65M USD
Revenue/Share—
Last Price1.110 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.35
PEG—
EV/EBITDA-0.33
EV/Revenue—
P/S—
P/B1.48
EPS (TTM)-4.84
EPS (Forward)-3.25
52W Range
0.62014% of range12.40
52W High12.40 USD
52W Low0.6201 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-302.89%
ROA-193.85%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-16.39M USD
CapEx (TTM)262.00K USD
FCF Margin—
FCF Yield-108.37%
Net Debt-2.05M USD
Net Debt/EBITDA0.12
Balance Sheet
Debt/Equity0.39
Current Ratio2.64
Quick Ratio1.59
Book Value/Sh0.76 USD
Cash/Share0.53 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateMar 30, 2026
Analyst Consensus
Rating—
Target (Mean)12.50 USD
Upside (mean)+1026.1%
Target Range6.000 USD – 19.00 USD
6.000+1026.1% to mean19.00
# Analysts2
Ownership
Shares Out.6.96M
Float5.19M
Insiders13.74%
Institutions14.87%
Short Interest
Short Ratio2.0d
Short % Float9.97%
Short % Out.9.51%
Shares Short661.91K
Short (prev mo.)141.71K
Technical
SMA 501.284 (-13.5%)
SMA 2002.816 (-60.6%)
Beta1.74
S&P 52W Chg16.45%
Avg Vol (30d)239.03K
Avg Vol (10d)142.06K
Technical Indicators
RSI (14)37.6
MACD-0.0542
MACD Signal-0.0069
MACD Hist.-0.0473
BB Upper1.734 USD
BB Middle1.364 USD
BB Lower0.9940 USD
BB Width54.23%
ATR (14)0.1376 USD
Vol Ratio (20d)0.50x